Faeth Therapeutics partners with Roche on breast cancer combination trial
Faeth Therapeutics entered a clinical trial collaboration and supply agreement with Roche to evaluate PIKTOR with investigational giredestrant in a Phase 1b/2 study.
1. Trial collaboration
The study will evaluate the combination in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Faeth will sponsor and conduct the trial, while Roche will supply giredestrant.





